<DOC>
	<DOCNO>NCT02371460</DOCNO>
	<brief_summary>The aim randomize control trial determine whether docosahexaenoic acid ( DHA , omega-3 lipid ) supplementation lactate mother provide breast-milk infant bear 29 0/7 week gestational age ( GA ) improve BPD-free survival 36 week post-menstrual age ( PMA ) . Half participant receive docosahexaenoic acid ( DHA ) , omega-3 lipid , half receive placebo .</brief_summary>
	<brief_title>Maternal Omega-3 Supplementation Reduce Bronchopulmonary Dysplasia</brief_title>
	<detailed_description>Every year Canada , 1500 baby bear early ( prematurely ) develop serious lung disease call bronchopulmonary dysplasia ( BPD ) . BPD cause major health problem infant , especially early childhood . In situation , breast-milk ideal source nutrition growth development premature baby . However , diet Canadian mother generally deficient omega-3 lipid ( essential fat ) , result low protection omega-3 lipid mother 's milk-fed infant . Previous research show give DHA mother premature baby safe mother baby , efficient way help baby meet dietary requirement breast-milk . Furthermore , previous research also suggest intervention may reduce risk BPD premature baby receive breast-milk .</detailed_description>
	<mesh_term>Bronchopulmonary Dysplasia</mesh_term>
	<criteria>1 . Age equal 16 year 2 . Preterm delivery ( 230/7 286/7 week gestation ) 3 . No contraindication breastfeed 4 . Subject intend provide breast milk infant 5 . Randomization 72 hour post delivery MOTHERS 1 . Mother take &gt; 250 mg daily DHA supplementation last 3 month 2 . Mother currently enrol participate another clinical trial receive investigational drug intervention within 3 month date randomization ( unless approve Trial Coordinating Centre ) 3 . Inability comprehend comply study requirement 4 . Participation study previous pregnancy INFANTS 1 . Significant congenital malformation infant ( one infants case multiple pregnancy ) 2 . Infant ( one infants case multiple pregnancy ) currently enrol another clinical trial ( unless approve Trial Coordinating Centre )</criteria>
	<gender>Female</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Neonatal Prematurity</keyword>
	<keyword>Omega-3 Fatty Acids</keyword>
	<keyword>Breastfeeding</keyword>
</DOC>